Sensorion Presents Hearing Loss Therapy Innovations at J.P. Morgan Conference

Biotech company showcases gene therapy and small molecule programs targeting various forms of deafness

Apr. 13, 2026 at 4:43am by

Got story updates? Submit your updates here. ›

A glowing, vibrant neon outline of a human ear against a dark background, conceptually representing Sensorion's work in developing therapies to treat hearing loss disorders.Sensorion's innovative gene therapies and small molecule treatments aim to restore hearing and address the complexities of inner ear diseases.San Francisco Today

Sensorion, a biotechnology company focused on developing treatments for hearing loss disorders, is set to present its innovative therapies at the prestigious 44th Annual J.P. Morgan Healthcare Conference in San Francisco. The company's CEO, Nawal Ouzren, will take the stage on January 15th, 2026, to discuss Sensorion's pipeline, which includes gene therapy programs targeting hereditary deafness and a small molecule candidate designed to preserve residual hearing in various conditions.

Why it matters

Hearing loss is a significant global medical need, and Sensorion's work in this area could potentially revolutionize the treatment of various forms of deafness. The company's unique R&D platform and its collaboration with the Institut Pasteur on genetics-based therapies are particularly noteworthy, as they aim to address the underlying causes of certain hereditary hearing disorders.

The details

Sensorion's pipeline includes two gene therapy programs: SENS-501 (OTOF-GT), which targets deafness caused by mutations in the otoferlin gene, and GJB2-GT, which focuses on hearing loss related to mutations in the GJB2 gene. The company is also developing a clinical-stage small molecule, SENS-401 (Arazasetron), designed to treat and prevent hearing loss disorders, including cisplatin-induced ototoxicity, hearing loss associated with cochlear implantation, and sudden sensorineural hearing loss.

  • The 44th Annual J.P. Morgan Healthcare Conference will take place from January 12th to 15th, 2026.
  • Sensorion's CEO, Nawal Ouzren, will present the company's innovations on January 15th, 2026, at 8:15 AM PT (5:15 PM CET).
  • Sensorion's SENS-501 (OTOF-GT) gene therapy program is currently in a Phase 1/2 clinical trial.
  • The company's small molecule, SENS-401 (Arazasetron), has progressed through three Phase 2 clinical studies for various hearing loss conditions.

The players

Sensorion

A biotechnology company at the forefront of developing therapies to restore, treat, and prevent hearing loss disorders.

Nawal Ouzren

The Chief Executive Officer of Sensorion, who will be presenting the company's innovations at the J.P. Morgan Healthcare Conference.

Institut Pasteur

Sensorion's collaborator on the development of gene therapy programs targeting the genetics of hearing loss.

Cochlear Limited

Sensorion's partner in a clinical study evaluating the use of SENS-401 (Arazasetron) for residual hearing preservation in patients scheduled for cochlear implantation.

Got photos? Submit your photos here. ›

What they’re saying

“Sensorion is working to address a significant global medical need, and we're excited to showcase our innovative therapies at the prestigious J.P. Morgan Healthcare Conference.”

— Nawal Ouzren, Chief Executive Officer, Sensorion

What’s next

Following Sensorion's presentation at the J.P. Morgan Healthcare Conference, the company will continue to advance its gene therapy and small molecule programs through clinical trials, with the goal of bringing new treatments for hearing loss disorders to market.

The takeaway

Sensorion's focus on developing innovative therapies to address the complex challenges of hearing loss disorders, including its collaboration with the Institut Pasteur and its progress in clinical trials, positions the company as a leader in this important and underserved medical field.